RELAPSED OR REFRACTORY B-CELL LYMPHOMA
Clinical trials for RELAPSED OR REFRACTORY B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED OR REFRACTORY B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED OR REFRACTORY B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug aims to keep lymphoma in check after CAR-T treatment
Disease control Not yet recruitingThis study tests whether the drug pirtobrutinib can help prevent relapse in people with B-cell lymphoma who have already received CAR-T cell therapy. Twenty adults will take pirtobrutinib daily for six months after their CAR-T infusion. The main goal is to see how many achieve a …
Matched conditions: RELAPSED OR REFRACTORY B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Experimental Dual-Targeting T-Cell therapy takes on tough lymphomas
Disease control Not yet recruitingThis early-phase trial will test a new type of immune cell therapy called bispecific AbTCR T-cells in 3 adults with relapsed or refractory B-cell lymphoma (including diffuse large B-cell, follicular, and Burkitt lymphoma). The cells are designed to target two proteins (CD19 and C…
Matched conditions: RELAPSED OR REFRACTORY B-CELL LYMPHOMA
Phase: EARLY_PHASE1 • Sponsor: First Affiliated Hospital Xi'an Jiaotong University • Aim: Disease control
Last updated Jun 26, 2026 17:44 UTC